A New Approach to Alzheimer’s? Leucadia Therapeutics | MedTech World Middle East 2026

Why It Matters

Targeting the brain’s waste‑clearance system could shift Alzheimer’s treatment from symptom management to disease modification, opening pathways for multiple neurodegenerative conditions.

Key Takeaways

• Glymphatic dysfunction linked to early Alzheimer’s
• Leucadia's Arethusta modulates CSF outflow
• $5M Series A funds 15‑patient pilot
• First‑in‑human trial starts in California
• Platform may treat FTD, Long COVID, stroke

Pulse Analysis

The glymphatic system, a network of perivascular channels that clears metabolic waste from the brain, has emerged as a promising target for neurodegenerative disease research. Recent studies suggest that age‑related narrowing of the cribriform plate hampers cerebrospinal fluid drainage, allowing toxic proteins such as amyloid‑β to accumulate in the medial temporal lobe—the region first affected in Alzheimer’s. By enhancing this natural clearance pathway, Leucadia Therapeutics hopes to intervene before irreversible neuronal loss occurs, positioning Arethusta as a potential disease‑modifying therapy rather than a symptomatic remedy.

Leucadia’s preclinical work in ferrets demonstrated that modulating glymphatic flow reduces amyloid deposition and improves cognitive markers, providing a translational bridge to human trials. The upcoming first‑in‑human study, backed by a $5 million Series A round, will enroll fifteen participants in California to assess safety, dosing, and preliminary efficacy. If successful, the trial could validate a novel mechanism of action, attracting interest from investors and pharmaceutical partners seeking to diversify the Alzheimer’s pipeline, which has been dominated by amyloid‑targeting antibodies.

Beyond Alzheimer’s, the glymphatic platform holds relevance for a spectrum of neurological disorders where waste clearance is compromised. Frontotemporal dementia, post‑COVID neurological sequelae, Down syndrome‑related cognitive decline, and stroke recovery all exhibit disrupted cerebrospinal fluid dynamics. Leucadia’s strategy to commercialize a minimally invasive modulator could therefore create a multi‑indication franchise, reshaping brain‑health therapeutics and offering new revenue streams in a market projected to exceed $30 billion by 2030.

Original Description

Can restoring the brain’s natural drainage system help address Alzheimer’s disease?

At MedTech World Middle East, Douglas Ethell, Founder & CEO of Leucadia Therapeutics, presented a novel approach targeting the glymphatic system — a key mechanism responsible for clearing waste from the brain.

Leucadia is developing Arethusta, a minimally invasive glymphatic modulator designed to enhance cerebrospinal fluid outflow. The company’s research suggests that impaired drainage at the cribriform plate may contribute to the early development of Alzheimer’s pathology.

In this Company Showcase:

• The science behind the glymphatic system

• Why Alzheimer’s pathology begins in the medial temporal lobe

• Age-related anatomical changes and loss of smell

• Preclinical ferret model findings

• First-in-human clinical trial launching in California

• $5M Series A to fund a 15-patient pilot study

• Expansion potential into FTD, Long COVID, Down syndrome & stroke recovery

With clinical trials ahead and multiple potential neurological indications, Leucadia Therapeutics is aiming to pioneer a new category in brain health innovation.

Watch the full showcase to learn more.

#MedTechWorld #AlzheimersResearch #NeuroInnovation #BrainHealth #HealthcareInnovation #StartupShowcase